File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)

Conference Paper: Revisiting oral fluoropyrimidine with cetuximab in metastatic colorectal cancer: Real-world data in Chinese population

TitleRevisiting oral fluoropyrimidine with cetuximab in metastatic colorectal cancer: Real-world data in Chinese population
Authors
Issue Date2019
Citation
World J Gastrointest Oncol, v. 11 n. 11, p. 1031-1042 How to Cite?
AbstractBACKGROUND: Cetuximab in combination with oral fluoropyrimidine (FP) remains controversial in metastatic colorectal cancer (mCRC). In view of the regional variation in the tolerability of FP, we conducted a retrospective analysis to compare oral FP with infusional FP in combination with cetuximab in Chinese population. AIM: To compare the efficacy and safety profile of cetuximab in combination with oral FP and infusional FP in Chinese population in the real-world setting. METHODS: A retrospective cohort study was done to analyse consecutive patients with Kras wild-type mCRC who received first-line treatment with cetuximab and FP-based chemotherapy in our unit from January 2010 to December 2015. Ninety-five eligible patients were included. The median follow-up of our cohort was 65.0 mo. RESULTS: The median progression-free survival (mPFS) and median overall survival (mOS) of the entire cohort were 9.66 mo (95%CI: 7.72-12.5) and 25.8 mo (95%CI: 18.7-35.6), respectively. Between oral FP and infusional FP, there was no statistical significant difference in the mPFS [9.79 mo (95%CI: 7.49-12.7) vs 9.63 mo (95%CI: 6.34-13.4); P = 0.72] and mOS [25.8 mo (95%CI: 15.2-35.6) vs 26.3 mo (95%CI: 18.7-41.2); P = 0.63]. Grade 3 or above adverse events were reported in 28.4% of patients, being similar with oral and infusional FP, and included 10.5% of neutropenia and 2.1% of diarrhoea events. CONCLUSION: The current analysis demonstrates comparable efficacy and safety profiles of cetuximab in combination with oral and infusional FP in Chinese population. The results expand treatment options for Chinese patients and invite revision of existing treatment guidelines to incorporate oral FP-based chemotherapy plus cetuximab.
Persistent Identifierhttp://hdl.handle.net/10722/293880

 

DC FieldValueLanguage
dc.contributor.authorLam, KO-
dc.contributor.authorFu, MC-
dc.contributor.authorLau, KS-
dc.contributor.authorLam, KM-
dc.contributor.authorChoi, CW-
dc.contributor.authorChiu, WHK-
dc.contributor.authorYuen, CM-
dc.contributor.authorKwok, LH-
dc.contributor.authorTam, FK-
dc.contributor.authorChan, WLW-
dc.contributor.authorChan, SYA-
dc.contributor.authorHo, PYP-
dc.contributor.authorLeung, TW-
dc.contributor.authorLee, VHF-
dc.date.accessioned2020-11-23T08:23:10Z-
dc.date.available2020-11-23T08:23:10Z-
dc.date.issued2019-
dc.identifier.citationWorld J Gastrointest Oncol, v. 11 n. 11, p. 1031-1042-
dc.identifier.urihttp://hdl.handle.net/10722/293880-
dc.description.abstractBACKGROUND: Cetuximab in combination with oral fluoropyrimidine (FP) remains controversial in metastatic colorectal cancer (mCRC). In view of the regional variation in the tolerability of FP, we conducted a retrospective analysis to compare oral FP with infusional FP in combination with cetuximab in Chinese population. AIM: To compare the efficacy and safety profile of cetuximab in combination with oral FP and infusional FP in Chinese population in the real-world setting. METHODS: A retrospective cohort study was done to analyse consecutive patients with Kras wild-type mCRC who received first-line treatment with cetuximab and FP-based chemotherapy in our unit from January 2010 to December 2015. Ninety-five eligible patients were included. The median follow-up of our cohort was 65.0 mo. RESULTS: The median progression-free survival (mPFS) and median overall survival (mOS) of the entire cohort were 9.66 mo (95%CI: 7.72-12.5) and 25.8 mo (95%CI: 18.7-35.6), respectively. Between oral FP and infusional FP, there was no statistical significant difference in the mPFS [9.79 mo (95%CI: 7.49-12.7) vs 9.63 mo (95%CI: 6.34-13.4); P = 0.72] and mOS [25.8 mo (95%CI: 15.2-35.6) vs 26.3 mo (95%CI: 18.7-41.2); P = 0.63]. Grade 3 or above adverse events were reported in 28.4% of patients, being similar with oral and infusional FP, and included 10.5% of neutropenia and 2.1% of diarrhoea events. CONCLUSION: The current analysis demonstrates comparable efficacy and safety profiles of cetuximab in combination with oral and infusional FP in Chinese population. The results expand treatment options for Chinese patients and invite revision of existing treatment guidelines to incorporate oral FP-based chemotherapy plus cetuximab.-
dc.languageeng-
dc.relation.ispartofWorld J Gastrointest Oncol-
dc.titleRevisiting oral fluoropyrimidine with cetuximab in metastatic colorectal cancer: Real-world data in Chinese population-
dc.typeConference_Paper-
dc.identifier.emailLam, KO: lamkaon@hku.hk-
dc.identifier.emailLau, KS: lauks18@hku.hk-
dc.identifier.emailLam, KM: kamlam@hku.hk-
dc.identifier.emailChoi, CW: hcchoi@hku.hk-
dc.identifier.emailChiu, WHK: kwhchiu@hku.hk-
dc.identifier.emailYuen, CM: ycm630@hku.hk-
dc.identifier.emailChan, WLW: winglok@hku.hk-
dc.identifier.emailHo, PYP: pattyho@hku.hk-
dc.identifier.emailLeung, TW: ltw920@hkucc.hku.hk-
dc.identifier.emailLee, VHF: vhflee@hku.hk-
dc.identifier.authorityLam, KO=rp01501-
dc.identifier.authorityChiu, WHK=rp02074-
dc.identifier.authorityChan, WLW=rp02541-
dc.identifier.authorityLee, VHF=rp00264-
dc.identifier.doi10.4251/wjgo.v11.i11.1031-
dc.identifier.hkuros320298-
dc.identifier.volume11-
dc.identifier.issue11-
dc.identifier.spage1031-
dc.identifier.epage1042-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats